25 February 2025 - Innorna is thrilled to announce that the US FDA has granted rare paediatric disease designation to its investigational mRNA therapy, IN013, for the treatment of Wilson disease, also known as hepatolenticular degeneration, a severe genetic disorder.

This milestone underscores the potential of Innorna’s mRNA-LNP technology platform and will significantly accelerate the clinical development of IN013, propelling Innorna closer to providing a transformative therapy for patients with Wilson disease.

Read Innorna press release